Table 4

Adherence to guidelines across 84 primary car practices*
Process of care manoeuvre Percentage of patients receiving care [95% CI]
All (n = 4931)
 2 Blood pressure measures 74.8% [71.3-78.3%]
 Lipid profile 77.7% [74.9-80.4%]
 Waist circumference measure 9.9% [6.7-13.0%]
 Dietician/weight loss program referral 18.2% [14.3-22.2%]
 Smoking status recorded 95.4% [93.9-97.0%]
Coronary Artery Disease (n = 1510)
 Fasting blood glucose 80.0% [77.2-82.8%]
 Medication (ACE, Angiotensin receptor blocker, beta blocker) 88.5% [86.5-90.4%]
 ASA 76.0% [73.2-78.9%]
Peripheral Vascular Disease (n = 318)
 Fasting blood glucose 78.9% [74.6-83.2%]
 ACE inhibitor and/or Angiotensin receptor blocker 66.9% [61.4-72.5%]
 Lipid lowering medication 83.3% [77.8-88.8%]
 ASA 75.8% [70.3-81.2%]
Stroke (n = 636)
 Fasting blood glucose 76.9% [72.8-81.0%]
 ASA 78.9% [74.7-83.2%]
If stroke within past year (n = 71)
 Echo cardiogram 47.9% [38.6-65.6%]
 Carotid doppler 59.6% [43.7-74.7%]
 CT head scan 66.2% [52.6-79.8%]
 EKG 52.1% [38.6-65.6%]
Diabetes (n = 2308)
 Two hemoglobin A1c tests 54.9% [50.1-59.6%]
 Glycemic control medication 80.5% [78.0-83.0%]
 ACR 55.8% [50.6-61.0%]
 eGFR 83.8% [80.8-86.8%]
Chronic Kidney Disease (n = 916)
 ACR 51.6% [46.3-57.0%]
Dyslipidemia (n = 4111)
 Lipid profile 82.8% [80.9-84.7%]
 Lipid lowering medication 91.5% [90.1-92.8%]
Hypertension (n = 3793)
 Two blood pressure readings 79.4% [76.0-82.8%]
 Anti-Hypertensive medication 94.2% [93.1-95.3%]
Smoking (n = 1049)
 Smoking cessation counselling 52.8% [46.9-58.8%]
 Smoking cessation program 7.7% [5.1-10.6%]
 Smoking cessation drug 23.1% [19.2-27.1%]

ACE Angiotensin converting enzyme, ACR Albumin to creatinine ratio, ASA Acetylsalicylic acid, CT Computed Tomography, eGFR estimated glomerular filtration rate, EKG Electrocardiogram.

* assessed whether recommended manoeuvres were performed, recommended, or discussed during the one year preceding the abstraction date.

Liddy et al.

Liddy et al. BMC Cardiovascular Disorders 2012 12:74   doi:10.1186/1471-2261-12-74

Open Data